Pieris Pharmaceuticals, Inc. — Form 10-Q Summary
Filing identity: The supplied filing is for Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS), not “Pavella Therapeutics, Inc.” It covers the quarter and nine months ended September 30, 2023; filed November 14, 2023. Financial amounts below are in U.S. dollars.
Business context and reporting period
Pieris is a clinical-stage biotechnology company with Anticalin-based drug programs and pharmaceutical collaborations. It has no product-sales revenue. Following setbacks in its respiratory portfolio, the company is pursuing strategic alternatives—including a sale, merger, asset sale, or partnerships—and substantially scaled back operations.
In July 2023, Pieris approved a workforce reduction of approximately 70%. It stopped planned investment in PRS-220 phase 2a readiness and PRS-400 research and development, and opted out of U.S. co-development of PRS-344/S095012. The company says its remaining limited operations are funded for at least 12 months from the filing’s issuance, based on its budget and planned cost controls.
Key financial metrics
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $19.5 million | $5.4 million | $41.5 million | $20.1 million |
| Operating expenses | $31.3 million | $17.5 million | $66.8 million | $52.0 million |
| Operating loss | $11.8 million | $12.2 million | $25.3 million | $32.0 million |
| Net loss | $10.8 million | $9.7 million | $20.0 million | $25.2 million |
| Basic and diluted loss per share | $0.11 | $0.13 | $0.23 | $0.34 |
| Operating cash used | Not provided for quarter | Not provided for quarter | $34.2 million | $47.0 million |
At September 30, 2023, cash and cash equivalents were $32.9 million and short-term investments were $11.9 million, totaling $44.8 million. Total assets were $59.4 million; total liabilities were $28.9 million, including $12.3 million of operating lease liabilities. The filing reports no borrowings. Gross margin is not meaningful because the company has no product sales and reports no product cost of sales.
Cash and cash equivalents declined by $5.7 million during the first nine months. Investing activities provided $8.6 million, primarily reflecting investment maturities, while financing activities provided $19.8 million, principally from at-the-market (ATM) share sales. The accumulated deficit was $310.4 million.
Material changes versus comparable periods
- Q3 revenue increased $14.2 million year over year, driven chiefly by event-related recognition: approximately $9.0 million following a Seagen collaboration amendment, $3.5 million from AstraZeneca agreement termination, and a $2.5 million Boston Pharmaceuticals milestone. These items are not necessarily recurring.
- Nine-month revenue rose $21.5 million, mainly from recognition associated with Genentech program discontinuations, AstraZeneca program discontinuations and termination, the Seagen amendment, and the Boston Pharmaceuticals milestone.
- Q3 operating expenses increased $13.8 million, largely because of a $14.9 million asset impairment; R&D expense fell to $9.6 million from $13.6 million, while G&A rose to $6.8 million from $3.9 million. Nine-month R&D declined to $37.3 million from $39.6 million.
- The $14.9 million impairment reflected plans to sell German-site property and equipment and write-downs of leasehold improvements and other long-lived assets. Pieris estimated $2.1 million of equipment and furniture remained recoverable at fair value less selling costs.
- Restructuring costs were approximately $6.8 million, including severance and related benefits expected to be paid through Q2 2024.
- Pieris raised $20.3 million gross through its ATM program in the first nine months by selling 24.3 million shares at an average $0.84 per share. Shares outstanding rose from 74.5 million at year-end 2022 to 98.9 million at September 30, 2023.
Outlook, management commentary and risks
- Management expects materially lower near-term operating cash requirements due to the workforce reduction, project limitations, and strategic review. The stated minimum 12-month runway is an estimate and depends on spending controls and other assumptions.
- No definitive strategic transaction, timetable, or board-approved course of action had been established. Pieris warned that a transaction may not occur or may not provide value; if none occurs, the board may consider dissolution and liquidation.
- AstraZeneca stopped elarekibep clinical dosing after nonclinical toxicology findings that included respiratory-tract pathology and inflammation-mediated lung damage. AstraZeneca’s termination of the collaboration became effective October 15, 2023.
- Genentech and Pieris discontinued their respiratory and ophthalmology discovery programs. Pieris recognized the remaining $12.5 million of Genentech revenue in Q2 2023.
- Pieris opted out of U.S. co-development and commercialization of PRS-344/S095012; Servier retains worldwide rights. Pieris says it is eligible for increased royalties and potential milestones.
- Seagen assumed substantially all activities previously performed by Pieris under an amendment, resulting in approximately $9.0 million of Q3 revenue recognition. Boston Pharmaceuticals’ PRS-342/BOS-342 study began dosing its first patient in August 2023; Pieris received a $2.5 million milestone.
- Potential future collaboration milestones are contingent on development, regulatory, commercial, and sales outcomes and are not assured. The filing lists up to $947 million of research, development, regulatory and commercial milestones and $810 million of sales milestones across specified collaborations.
- Nasdaq had notified Pieris that it was below the $1.00 minimum bid-price requirement. A second 180-day compliance period, through May 13, 2024, was granted after the filing period; Pieris said it may use a reverse stock split if necessary. Delisting could impair liquidity, financing, and strategic options.
- The company may face costs or grant repayment obligations related to strategic transactions, including under the Bavarian PRS-220 grant, and continues to evaluate options for its German facility lease. It reported no material pending legal proceedings and said disclosure controls were effective.
Most important facts for investors to verify
- Whether Pieris completes a strategic transaction, partnership, asset sale, or other course of action, and the terms and value delivered to shareholders.
- Actual cash burn and runway relative to management’s estimate, including transaction costs, lease obligations, severance, and any grant repayment exposure.
- Progress toward Nasdaq bid-price compliance by May 13, 2024, and whether a reverse split or delisting occurs.
- Whether collaboration programs advance and generate future milestones, royalties, or other payments; these are uncertain and event-driven Q3 revenue should not be assumed recurring.
- Shares issued under the ATM program, remaining financing capacity, and potential further dilution.
- Recoverable proceeds from the planned asset sale and the costs or liabilities associated with exiting the Hallbergmoos lease.